Efficacy of rhenium-186-Etidronate in prostate cancer patients with metastatic bone pain

Journal of Nuclear Medicine

Volumn 37, Issue 9, 1996, Pages 1511-1515

  Quirijnen, Jac M S P ^a   Han, Shiuw H ^a   Zonnenberg, Bernard A ^a   De Klerk, John M H ^a   Van Het Schip, Alfred D ^a   Van Dijk, Aalt ^a   Ten Kroode, Herman F J ^a   Blijham, Geert H ^a   Van Rijk, Peter P ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

bone metastases; pain response; prostate cancer; rhenium 186 HEDP

Indexed keywords

ETIDRONIC ACID RE 186; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BONE METASTASIS; BONE PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PAIN ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER;

BONE NEOPLASMS; ETIDRONIC ACID; HUMANS; MALE; PAIN MEASUREMENT; PALLIATIVE CARE; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOTHERAPY DOSAGE; RHENIUM; TIME FACTORS;

EID: 0029761495     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Maxon HR, Deutsch EA, Thomas SR, et al. Rhenium-186(Sn)HEDP for treatment of multiple metastatic foci in bone: human biodistribution and dosimetric studies. Radiology 1988;166:501-507.
2. Maxon HR, Schroder LE, Hertzberg VS, et al. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. J Nucl Med 1991;32:1877-1881.
3. Maxon HR, Thomas SR, Hertzberg VS, et al. Rhenium-186-hydroxyethylidene diphosphonate for the treatment of painful bone metastases. Semin Nucl Med 1992;22:33-40.
4. Maxon HR, Schroder LE, Thomas SR, et al. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer. Radiology 1990;176:155-159.
5. de Klerk JMH, van Dijk A, van het Schip AD, Zonnenberg BA, van Rijk PP. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases. J Nucl Med 1992;33:646-651.
6. de Klerk JMH, Zonnenberg BA, van het Schip AD, et al. Dose escalation study of rhenium-186-hydroxyethylidene diphosphonate in patients with metastatic prostate cancer. Eur J Nucl Med 1994;21:1121-1125.
7. de Klerk JMH, van het Schip AD, Zonnenberg BA, et al. Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations. J Nucl Med 1994;35:1423-1428.
8. de Klerk JMH, van het Schip AD, Zonnenberg BA, van Dijk A, Blijham GH, van Rijk PP. Phase 1 study of re-186-HEDP in patients with bone metastases originating from breast cancer. J Nucl Med 1996;37:244-249.
9. Melzack R, Katz J. Pain measurement in persons in pain. In: Wall PD, Melzack R, eds. Textbook of pain. Edinburgh: Churchill Livingston; 1994:277-299.
10. Ahles TA, Blanchard EB, Ruckdeschel JC. The multidimensional nature of cancer-related pain. Pain 1983;17:277-288.
11. Grossman SA, Sheidler VR, Swedeen K, Mucenski J, Piantadosi S. Correlation of patient and caregiver rating of cancer pain. J Pain Symptom Management 1991;6:53-57.
12. Cleeland CS. Barriers to the management of cancer. Oncology 1987;1:19-26.
13. Dunkel-Schetter C, Wortman CB. The interpersonal dynamics of cancer: problems in social relationship and their impact on the patient. In: Friedman HS, Dimatto MR, eds. Interpersonal issues in health care. New York: Academic Press; 1982:69-100.
14. Lewis B, Lewis D, Cumming G. Frequent measurement of chronic pain: an electronic diary and empirical findings. Pain 1995;60:341-347.
15. Melzack R. The McGill pain questionnaire: major properties and scoring methods. Pain 1975;1:277-299.
16. Foley KM. The treatment of cancer pain. N Engl J Med 1985;313:84-95.
17. Blake GM, Zivanovic MA, McEwan AJ, Ackery DM. Strontium-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med 1986; 12:447-454.
18. Quilty PM, Kirk D, Bolger JJ, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994;31:33-40.
19. Porter AT, McEwan AJB, Powe JE, et al. Results of a randomized phase III trial to evaluate the efficacy of strontium-86 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys, 1993;25:805-813.
20. Tong D, Gillick L, Hendrickson FR. The palliation of symptomatic osseous metastases. Final results of the study by the Radiation Oncology Group. Cancer 1982;50: 893-899.